
    
      The purpose of this study is to evaluate the safety and immune response of the RSV MEDI Î”M2-2
      vaccine in the four groups of participants. The study vaccine will be evaluated in adults, in
      RSV-seropositive children, and in a dose-ranging study in two groups of RSV-seronegative
      infants and children.
    
  